Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRBP vs ANRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–1 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: CRBP 2 – 2 ANRO (2 Tie) Matrix Metrics: CRBP 1 – 5 ANRO

As of Nov 16, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CRBP carries a Unified Composite Score of 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin), whereas ANRO carries 29.2/100 (SELL) at $27.12 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CRBP currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. ANRO 29.2/100 SELL), ANRO captures the overall institutional head-to-head verdict (5–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: CRBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3); meanwhile ANRO is in a Breakdown options structure phase (RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRBP vs ANRO
CRBP NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap $69.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.93β · 121% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 43.0 Fund 54.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -32.8%), weak momentum, RSI 34
RSI-14: 34.3 · SMA20: $3.83 · SMA50: $5.51
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.12
-8.19% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.95β · 90% Vol
Unified Composite Score
29.2 / 100 SELL
Tech 50.0 Fund 33.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.3 · SMA20: $24.83 · SMA50: $26.20

6-Pillar Scorecard Institutional Category Breakdown (CRBP 2 – 2 ANRO)

Columns: Metric · CRBP · ANRO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ANRO
Revenue Growth (YoY) -100.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $69.9M $1.2B
3. Profitability & Quality ANRO
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -131.5% -46.7%
4. Balance Sheet & Cash Flow CRBP
Cash Generation (TTM) -$92M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $26M Net Cash $301M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRBP
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 197.6% (66th %ile) 79.4% (8th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRBP (1) vs ANRO (5)
Institutional Metric CRBP ANRO Criterion Row Edge
Market Capitalization
Scale
$69.9M $1.2B Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +0.0% Higher Growth ANRO
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-131.5% -46.7% Higher ROE ANRO
52-Week Range Position
Momentum
6% ($3–$13) 61% ($11–$37) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
1.93β · 121% Vol 1.95β · 90% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
45.0 / 100 (HOLD) 29.2 / 100 (SELL) Higher Composite CRBP
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$92M ($26M Net Cash) -$80M ($301M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +48.94 pp
CRBP: -25.33% · ANRO: +23.61%
3M Horizon ANRO +45.98 pp
CRBP: -66.52% · ANRO: -20.54%
6M Horizon ANRO +90.48 pp
CRBP: -66.08% · ANRO: +24.4%
1Y Horizon ANRO +208.45 pp
CRBP: -69.51% · ANRO: +138.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRBP vs ANRO. Trailing 12-month operating profitability (CRBP 0.0% vs ANRO 0.0%) and valuation multiples (CRBP N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CRBP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-131.5% · N/M
ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRBP BREAKDOWN
58d in phase · OBV NEUTRAL
Current IV 197.6%
IV Percentile 66th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
57d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $69.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRBP vs ANRO Key Questions & Quantitative Answers

As of Nov 16, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CRBP carries a Unified Composite Score of 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin), whereas ANRO carries 29.2/100 (SELL) at $27.12 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CRBP currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. ANRO 29.2/100 SELL), ANRO captures the overall institutional head-to-head verdict (5–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: CRBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3); meanwhile ANRO is in a Breakdown options structure phase (RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: CRBP posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CRBP generates N/A in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, CRBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.

CRBP and ANRO trade at balanced relative valuation multiples. CRBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRBP (-131.5% ROE) versus ANRO (-46.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CRBP carries 197.6% implied volatility (66th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.93β · 121% Vol realized risk). By comparison, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.95β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.